Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It

With acquisition of biotech Proteolix for $276 million upfront (and another $535 million in milestones), Onyx gains a promising multiple myeloma drug.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet